Table 3.
Relationship between treatment failure and the number of risk factors in each phase in the overall population
| Number of risk factorsa | Treatment failure | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall (0–120 h) | Acute (0–24 h) | Delayed (24–120 h) | Extended overall (0–168 h) | Extended delayed (24–168 h) | Beyond delayed (120–168 h) | |||||||
| N | n (%) | N | n (%) | N | n (%) | N | n (%) | N | n (%) | N | n (%) | |
| 0 | 268 | 45 (16.8) | 161 | 7 (4.3) | 268 | 39 (14.6) | 286 | 53 (18.5) | 268 | 46 (17.2) | 953 | 39 (4.1) |
| 1 | 477 | 112 (23.5) | 467 | 16 (3.4) | 477 | 103 (21.6) | 494 | 141 (28.5) | 476 | 122 (25.6) | 411 | 194 (47.2) |
| 2 | 329 | 115 (35.0) | 441 | 30 (6.8) | 329 | 109 (33.1) | 328 | 128 (39.0) | 329 | 119 (36.2) | 0 | – |
| 3 | 180 | 79 (43.9) | 222 | 34 (15.3) | 180 | 79 (43.9) | 175 | 81 (46.3) | 180 | 83 (46.1) | 0 | – |
| 4 | 83 | 40 (48.2) | 66 | 20 (30.3) | 82 | 39 (47.6) | 74 | 42 (56.8) | 82 | 41 (50.0) | 0 | – |
| 5 | 28 | 21 (75.0) | 10 | 5 (50.0) | 28 | 20 (71.4) | 9 | 7 (77.8) | 28 | 20 (71.4) | 0 | – |
| 6 | 2 | 1 (50.0) | 1 | 0 (0.0) | 2 | 1 (50.0) | 0 | – | 2 | 1 (50.0) | 0 | – |
| Cochran–Armitage trend test | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||||||
To calculate “rarely” in “drinking history (no or rarely/yes),” patients who drank “once a month or once a week” in each original study were combined. “Yes” indicates patients who drank “every day” in each original study. To calculate “yes” in “smoking history (no/yes),” patients “who stopped smoking prior to 180 days before enrollment, those who stopped smoking within 180 days before enrollment, and current smokers” in each original study were combined. Data were obtained from the full analysis set
NK-1RA neurokinin 1 receptor antagonist
aRisk factors (overall): sex (female), performance status (1), drinking history 1 (no or rarely), smoking history 1 (no), motion sickness (yes), NK-1RA (placebo). Risk factors (acute): age (< 55), sex (female), drinking history 1 (no or rarely), motion sickness (yes), cisplatin dose (≥ 80 mg/m2), NK-1RA (placebo). Risk factors (delayed): sex (female), performance status (1), drinking history 1 (no or rarely), smoking history 1 (no), motion sickness (Yes), NK-1RA (placebo). Risk factors (0–168 h): sex (female), performance status (1), drinking history 1 (no or rarely), smoking history 1 (no), NK-1RA (placebo). Risk factors (24–168 h): sex (female), performance status (1), drinking history 1 (no or rarely), smoking history 1 (no), motion sickness (Yes), NK-1RA (placebo). Risk factors (120–168 h): Treatment failure in 0–120 h (yes)